Pulse Biosciences Reports Q4 2025 Earnings Beat Despite Share Sale Agreement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy PLSE?
Source: seekingalpha
- Earnings Beat: Pulse Biosciences reported a Q4 2025 non-GAAP net loss of $0.26 per share on revenues of $264K, exceeding Street forecasts by $0.05 and $10K respectively, although the overall performance remains weak.
- Equity Sale Agreement: The company has entered into an agreement with TD Securities to sell up to approximately $60 million worth of common stock, with TD acting as the sales agent and earning a commission of up to 3%, aimed at bolstering the company's liquidity.
- Liquidity Decline: As of December 31, Pulse's cash and cash equivalents dropped about 32% year-over-year to $80.7 million, indicating pressure on the company's financial management that could impact future operational capabilities.
- Market Reaction: Despite the earnings beat, Pulse's stock traded lower following the announcement, reflecting investor concerns over the company's liquidity situation, which may affect its future financing capabilities and market confidence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PLSE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PLSE
Wall Street analysts forecast PLSE stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 18.990
Low
22.00
Averages
22.00
High
22.00
Current: 18.990
Low
22.00
Averages
22.00
High
22.00
About PLSE
Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s CellFX Nanosecond Pulsed-Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. It is pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation (AF) and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Its nsPFA Percutaneous Electrode System consists of a disposable, percutaneous, needle electrode for use with its CellFX Console. Its surgical cardiac ablation clamp is designed for use by cardiac surgeons during the surgical treatment of AF. The CellFX Console is a tunable, software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. It is also developing a Nanosecond PFA 360-degree Cardiac Catheter System.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pulse Biosciences Reports Q4 2025 Earnings Beat Despite Share Sale Agreement
- Earnings Beat: Pulse Biosciences reported a Q4 2025 non-GAAP net loss of $0.26 per share on revenues of $264K, exceeding Street forecasts by $0.05 and $10K respectively, although the overall performance remains weak.
- Equity Sale Agreement: The company has entered into an agreement with TD Securities to sell up to approximately $60 million worth of common stock, with TD acting as the sales agent and earning a commission of up to 3%, aimed at bolstering the company's liquidity.
- Liquidity Decline: As of December 31, Pulse's cash and cash equivalents dropped about 32% year-over-year to $80.7 million, indicating pressure on the company's financial management that could impact future operational capabilities.
- Market Reaction: Despite the earnings beat, Pulse's stock traded lower following the announcement, reflecting investor concerns over the company's liquidity situation, which may affect its future financing capabilities and market confidence.
See More
Pulse Biosciences to Present at TD Cowen Healthcare Conference
- Conference Announcement: Pulse Biosciences is scheduled to present its innovative nPulse™ technology at the 46th Annual TD Cowen Healthcare Conference in Boston on March 4, 2026, which is expected to garner significant attention from the healthcare industry.
- Technology Overview: The company's nPulse™ technology employs nanosecond pulsed field ablation (nsPFA™) energy to non-thermally clear cells while sparing adjacent noncellular tissue, showcasing its substantial potential in the medical field.
- Market Applications: Pulse Biosciences is actively pursuing the development of its nPulse technology for treating atrial fibrillation and in surgical soft tissue ablation, which could profoundly improve healthcare outcomes for patients and providers alike.
- Investor Information: The presentation will be available via live and recorded webcast on the company's investor website's
See More
Pulse Biosciences Q4 2025 Earnings Call Insights
- Significant Revenue Growth: Pulse Biosciences reported total revenue of $264,000 in Q4 2025, a 207% increase from $86,000 in Q3, indicating early commercial traction in capital and disposable device sales, which suggests enhanced future revenue potential.
- Accelerated Clinical Progress: The expansion of patient treatment in Europe and IDE approvals for cardiac clamp programs signify the nsPFA platform's advancement into late-stage clinical development for atrial fibrillation, potentially offering new solutions and strengthening market competitiveness.
- Strengthened Intellectual Property Position: In 2025, the company added 67 issued and 77 pending patents, totaling 250 granted and 180 pending patents, further solidifying its technological advantage in the soft tissue ablation market and laying a foundation for future commercialization.
- Enhanced Funding Flexibility: The announcement of a $200 million shelf registration aims to support upcoming clinical milestones, ensuring continued progress in FDA approvals and reimbursement certainty, thereby enhancing its capacity for market expansion.
See More
Pulse Biosciences Q4 Earnings Beat Expectations
- Earnings Highlights: Pulse Biosciences reported a Q4 GAAP EPS of -$0.26, beating expectations by $0.05, indicating improvements in cost control and operational efficiency, although the company remains in a loss position.
- Revenue Growth: The company achieved Q4 revenue of $0.26 million, exceeding expectations by $0.01 million, suggesting increasing market acceptance of its products, which may lay the groundwork for future sales growth.
- Conference Presentations: Pulse Biosciences showcased its developments at the 31st Annual AF Symposium and the 44th Annual J.P. Morgan Healthcare Conference, enhancing its visibility in the industry and potentially attracting investors and partners.
- Historical Financial Data: The historical financial data provided by the company offers investors a comprehensive performance background, aiding in the analysis of its long-term growth potential and market positioning.
See More
Pulse Biosciences Shares Surge on Positive nPulse Catheter Study Results
- Promising Clinical Data: Pulse Biosciences presented significant clinical data for its nPulse Cardiac Catheter at the Annual AF Symposium in Boston, demonstrating successful treatment outcomes for atrial fibrillation in 150 patients, showcasing rapid procedure times and minimal adverse effects, potentially positioning nPulse as a market leader.
- Stock Price Surge: PLSE shares rose 4.05% to $21.59 in premarket trading on Monday, trading 49% above its 20-day simple moving average, indicating strong short-term momentum, despite a 7.20% decline over the past 12 months.
- Technical Indicator Analysis: The current RSI stands at 75.62, indicating the stock is in overbought territory, while the MACD is above its signal line, reflecting bullish momentum; however, investors should exercise caution due to potential overextension.
- Market Performance Assessment: According to Benzinga Edge, Pulse Biosciences' stock scored 68.22 in momentum, indicating strong performance relative to the broader market, yet investors should remain vigilant given the overbought RSI condition and monitor for any signs of reversal.
See More
Pulse Biosciences Unveils Key Clinical Data for nPulse Catheter
- Clinical Data Release: Pulse Biosciences presented clinical data for its nPulse cardiac catheter at the 2026 AF Symposium, successfully treating 150 patients with atrial fibrillation, showcasing rapid procedure times and minimal adverse effects, highlighting the technology's potential in atrial fibrillation treatment.
- Study Results Validation: The results from a study of 165 patients validated the safety and efficacy of the nPulse catheter system, with CEO Paul LaViolette noting its clear advantages in lesion quality and speed, potentially establishing it as a first-in-class system.
- Optimistic Treatment Outlook: The data suggest that the nPulse catheter could reduce atrial fibrillation recurrence rates, typically ranging from 20-25%, as Pulse Biosciences prepares to treat additional patients in the U.S. and Europe, initiating a pivotal IDE study.
- Strong Stock Performance: Pulse Biosciences saw trading volume surge to 1.68 million shares, significantly above the average of 183,000 shares, with the stock price rising 38.02% to $14.95, indicating a strong bullish setup and potential breakout above the $20 resistance level.
See More
Pulse Biosciences Reports Q4 2025 Earnings Beat Despite Share Sale Agreement
- Earnings Beat: Pulse Biosciences reported a Q4 2025 non-GAAP net loss of $0.26 per share on revenues of $264K, exceeding Street forecasts by $0.05 and $10K respectively, although the overall performance remains weak.
- Equity Sale Agreement: The company has entered into an agreement with TD Securities to sell up to approximately $60 million worth of common stock, with TD acting as the sales agent and earning a commission of up to 3%, aimed at bolstering the company's liquidity.
- Liquidity Decline: As of December 31, Pulse's cash and cash equivalents dropped about 32% year-over-year to $80.7 million, indicating pressure on the company's financial management that could impact future operational capabilities.
- Market Reaction: Despite the earnings beat, Pulse's stock traded lower following the announcement, reflecting investor concerns over the company's liquidity situation, which may affect its future financing capabilities and market confidence.
See More
Pulse Biosciences to Present at TD Cowen Healthcare Conference
- Conference Announcement: Pulse Biosciences is scheduled to present its innovative nPulse™ technology at the 46th Annual TD Cowen Healthcare Conference in Boston on March 4, 2026, which is expected to garner significant attention from the healthcare industry.
- Technology Overview: The company's nPulse™ technology employs nanosecond pulsed field ablation (nsPFA™) energy to non-thermally clear cells while sparing adjacent noncellular tissue, showcasing its substantial potential in the medical field.
- Market Applications: Pulse Biosciences is actively pursuing the development of its nPulse technology for treating atrial fibrillation and in surgical soft tissue ablation, which could profoundly improve healthcare outcomes for patients and providers alike.
- Investor Information: The presentation will be available via live and recorded webcast on the company's investor website's
See More
Pulse Biosciences Q4 2025 Earnings Call Insights
- Significant Revenue Growth: Pulse Biosciences reported total revenue of $264,000 in Q4 2025, a 207% increase from $86,000 in Q3, indicating early commercial traction in capital and disposable device sales, which suggests enhanced future revenue potential.
- Accelerated Clinical Progress: The expansion of patient treatment in Europe and IDE approvals for cardiac clamp programs signify the nsPFA platform's advancement into late-stage clinical development for atrial fibrillation, potentially offering new solutions and strengthening market competitiveness.
- Strengthened Intellectual Property Position: In 2025, the company added 67 issued and 77 pending patents, totaling 250 granted and 180 pending patents, further solidifying its technological advantage in the soft tissue ablation market and laying a foundation for future commercialization.
- Enhanced Funding Flexibility: The announcement of a $200 million shelf registration aims to support upcoming clinical milestones, ensuring continued progress in FDA approvals and reimbursement certainty, thereby enhancing its capacity for market expansion.
See More
Pulse Biosciences Q4 Earnings Beat Expectations
- Earnings Highlights: Pulse Biosciences reported a Q4 GAAP EPS of -$0.26, beating expectations by $0.05, indicating improvements in cost control and operational efficiency, although the company remains in a loss position.
- Revenue Growth: The company achieved Q4 revenue of $0.26 million, exceeding expectations by $0.01 million, suggesting increasing market acceptance of its products, which may lay the groundwork for future sales growth.
- Conference Presentations: Pulse Biosciences showcased its developments at the 31st Annual AF Symposium and the 44th Annual J.P. Morgan Healthcare Conference, enhancing its visibility in the industry and potentially attracting investors and partners.
- Historical Financial Data: The historical financial data provided by the company offers investors a comprehensive performance background, aiding in the analysis of its long-term growth potential and market positioning.
See More
Pulse Biosciences Shares Surge on Positive nPulse Catheter Study Results
- Promising Clinical Data: Pulse Biosciences presented significant clinical data for its nPulse Cardiac Catheter at the Annual AF Symposium in Boston, demonstrating successful treatment outcomes for atrial fibrillation in 150 patients, showcasing rapid procedure times and minimal adverse effects, potentially positioning nPulse as a market leader.
- Stock Price Surge: PLSE shares rose 4.05% to $21.59 in premarket trading on Monday, trading 49% above its 20-day simple moving average, indicating strong short-term momentum, despite a 7.20% decline over the past 12 months.
- Technical Indicator Analysis: The current RSI stands at 75.62, indicating the stock is in overbought territory, while the MACD is above its signal line, reflecting bullish momentum; however, investors should exercise caution due to potential overextension.
- Market Performance Assessment: According to Benzinga Edge, Pulse Biosciences' stock scored 68.22 in momentum, indicating strong performance relative to the broader market, yet investors should remain vigilant given the overbought RSI condition and monitor for any signs of reversal.
See More
Pulse Biosciences Unveils Key Clinical Data for nPulse Catheter
- Clinical Data Release: Pulse Biosciences presented clinical data for its nPulse cardiac catheter at the 2026 AF Symposium, successfully treating 150 patients with atrial fibrillation, showcasing rapid procedure times and minimal adverse effects, highlighting the technology's potential in atrial fibrillation treatment.
- Study Results Validation: The results from a study of 165 patients validated the safety and efficacy of the nPulse catheter system, with CEO Paul LaViolette noting its clear advantages in lesion quality and speed, potentially establishing it as a first-in-class system.
- Optimistic Treatment Outlook: The data suggest that the nPulse catheter could reduce atrial fibrillation recurrence rates, typically ranging from 20-25%, as Pulse Biosciences prepares to treat additional patients in the U.S. and Europe, initiating a pivotal IDE study.
- Strong Stock Performance: Pulse Biosciences saw trading volume surge to 1.68 million shares, significantly above the average of 183,000 shares, with the stock price rising 38.02% to $14.95, indicating a strong bullish setup and potential breakout above the $20 resistance level.
See More
